NEOK Bio vs Tempus
Side-by-side comparison of AI visibility scores, market position, and capabilities
NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of innate immune modulators.
About
NEOK Bio is targeting neuroinflammation — the chronic activation of brain immune cells (microglia and astrocytes) — as a primary driver of neurodegeneration in Alzheimer's disease, ALS, and Parkinson's disease. The company's small molecule drug candidates modulate the NLRP3 inflammasome and related innate immune pathways in the brain, aiming to reduce the toxic inflammatory environment that kills neurons over time.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
About
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.